DMPI has broken resistance on positive interim results of its clinical cancer drug, VAL-083. Analyst have a price target of $12. Bullish price action on trend analysis, chart patterns, and shorts covering.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
